First-line treatment for nasopharyngeal cancer BeiGene PD-1 inhibitor combination significantly prolongs PFS in patients

On December 10, 2021, BeiGene announced that the anti-PD-1 antibody tislelizumab combined with chemotherapy, a phase 3 clinical trial for the first-line treatment of patients with recurrent/metastatic nasopharyngeal carcinoma reached the primary endpoint

Nasopharyngeal carcinoma is a malignant tumor that occurs in the mucosal epithelium of the nasopharyngeal area and is one of the common malignant tumors of the head and neck

A total of 263 patients were enrolled in this phase 3 clinical trial.

The median PFS of the tislelizumab group was 9.

Consistent PFS benefit was observed in most patient subgroups, regardless of patient's disease status, baseline liver metastasis index, and gender

The objective response rate and complete response rate of the tislelizumab group were 69.

The combination of tislelizumab and chemotherapy showed controllable safety, consistent with the known risks of each therapeutic drug, and no new safety signals were found

Dr.

Reference materials:

[1] BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021.